Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Ian Dryg

3PUBLICATIONS

56CO-AUTHORS

Cancer therapy (excl. chemotherapy and radiation therapy)Innate immunityMolecular targets

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (3)

Sort by Publication Date:

|Nov 20, 2025

Phase II Trial of Cabozantinib in Combination with Nivolumab for Advanced Extrapancreatic Neuroendocrine Tumors.

Kimberly J Perez, Nora Horick, Joanna Baginksa

|Sep 04, 2025

Immunoprofiling at an Institutional Scale Reveals That High Numbers of Intratumoral CD8<sup>+</sup> and PD-1<sup>+</sup> Cells Predict Superior Patient Survival Across Major Cancer Types Independent of Major Risk Factors.

Joao V Alessi, James R Lindsay, Anita Giobbie-Hurder

|Jan 11, 2024

Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung Cancer.

Biagio Ricciuti, Giuseppe Lamberti, Sreekar R Puchala

Pageof 1

Frequent Collaborators

3 joint publications

Kathleen Pfaff

2 joint publications

Biagio Ricciuti

2 joint publications

Lynette M Sholl

2 joint publications

Anita Giobbie-Hurder

2 joint publications

Alessandro Di Federico

2 joint publications

Mark M Awad

2 joint publications

Malini M Gandhi

2 joint publications

Peter Sorger

2 joint publications

Jason Weirather

2 joint publications

Bruce E Johnson

Frequent Collaborators

3 joint publications

Kathleen Pfaff

2 joint publications

Biagio Ricciuti

2 joint publications

Lynette M Sholl

2 joint publications

Anita Giobbie-Hurder

Top Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on : Jul 25, 2020

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1<sup>+</sup> Tim-3<sup>+</sup> CD8<sup>+</sup> T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1<sup>+</sup> Tim-3<sup>+</sup> CD8<sup>+</sup> T Cells

Published on : Feb 08, 2018

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on : Feb 07, 2021

See more related videos

Top Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on : Jul 25, 2020

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1<sup>+</sup> Tim-3<sup>+</sup> CD8<sup>+</sup> T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1<sup>+</sup> Tim-3<sup>+</sup> CD8<sup>+</sup> T Cells

Published on : Feb 08, 2018

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on : Feb 07, 2021

See more related videos